Simvastatin ameliorates low-dose streptozotocin-induced type 2 diabetic nephropathy in an experimental rat model

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 4, 2015, Pages 6388-6396

  Zhang, Siwei ^a   Xu, Huali ^a   Yu, Xiaofeng ^a   Wang, Yuchen ^a   Sun, Fanfan ^a   Sui, Dayuan ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

Oxidative stress; Rat; Simvastatin; Type 2 diabetic nephropathy

Indexed keywords

CAPTOPRIL; CHOLESTEROL; CONNECTIVE TISSUE GROWTH FACTOR; GLUCOSE; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; SIMVASTATIN; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE COURSE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; KIDNEY FUNCTION; KIDNEY STRUCTURE; LIPID DIET; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; TRANSMISSION ELECTRON MICROSCOPY; UREA NITROGEN BLOOD LEVEL;

RATTUS;

EID: 84931281989     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. [1] Pawan Krishan VA. Diabetic nephropathy: aggressive involvement of oxidative stress. J Pharm Educ Res 2011; 2: 7.
2. [2] Abe H, Matsubara T, Arai H and Doi T. Role of Smad1 in diabetic nephropathy: molecular mechanisms and implications as a diagnostic marker. Histol Histopathol 2011; 26: 531-541.
3. [3] Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S and Danesh FR. Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med (Maywood) 2008; 233: 4-11.
4. [4] Zhou X, Feng Y, Zhan Z and Chen J. Hydrogen sulfide alleviates diabetic nephropathy in a streptozotocin-induced diabetic rat model. J Biol Chem 2014; 289: 28827-28834.
5. [5] Cooper ME. Diabetes: treating diabetic nephropathy-still an unresolved issue. Nat Rev Endocrinol 2012; 8: 515-516.
6. [6] Rosen P, Nawroth PP, King G, Moller W, Tritschler HJ and Packer L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17: 189-212.
7. [7] Wagener FA, Dekker D, Berden JH, Scharstuhl A and van der Vlag J. The role of reactive oxygen species in apoptosis of the diabetic kidney. Apoptosis 2009; 14: 1451-1458.
8. [8] Sharma K and Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139-1146.
9. [9] Farris AB and Colvin RB. Renal Interstitial fibrosis: mechanisms and evaluation in: current opinion in nephrology and hypertension. Curr Opin Nephrol Hypertens 2012; 21: 289-300.
10. [10] Boor P and Floege J. Chronic kidney disease growth factors in renal fibrosis. Clin Exp Pharmacol Physiol 2011; 38: 441-450.
11. [11] Lee HB, Yu MR, Yang Y, Jiang Z and Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003; 14: S241-245.
12. [12] Rosario R and Prabhakar S. Lipids and diabetic nephropathy. Curr Diab Rep 2006; 6: 455-462.
13. [13] Almquist T, Jacobson SH, Mobarrez F, Nasman P and Hjemdahl P. Lipid-lowering treatment and inflammatory mediators in diabetes and chronic kidney disease. Eur J Clin Invest 2014; 44: 276-284.
14. [14] Moorhead JF, Chan MK, El-Nahas M and Varghese Z. Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 1982; 2: 1309-1311.
15. [15] Athyros VG, Mitsiou EK, Tziomalos K, Karagiannis A and Mikhailidis DP. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother 2010; 11: 723-730.
16. [16] Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
17. [17] Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V and Fuller JH. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
18. [18] Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F and Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 263-275.
19. [19] McFarlane SI, Muniyappa R, Francisco R and Sowers JR. Clinical review 145: Pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 2002; 87: 1451-1458.
20. [20] Kim CS, Sohn EJ, Kim YS, Jung DH, Jang DS, Lee YM, Kim DH and Kim JS. Effects of KIOM-79 on hyperglycemia and diabetic nephropathy in type 2 diabetic Goto-Kakizaki rats. J Ethnopharmacol 2007; 111: 240-247.
21. [21] Lenzen S. The mechanisms of alloxan-and streptozotocin-induced diabetes. Diabetologia 2008; 51: 216-226.
22. [22] Hall-Craggs M, Brenner DE, Vigorito RD and Sutherland JC. Acute renal failure and renal tubular squamous metaplasia following treatment with streptozotocin. Hum Pathol 1982; 13: 597-601.
23. [23] Tay YC, Wang Y, Kairaitis L, Rangan GK, Zhang C and Harris DC. Can murine diabetic nephropathy be separated from superimposed acute renal failure? Kidney Int 2005; 68: 391-398.
24. [24] Kraegen EW, Clark PW, Jenkins AB, Daley EA, Chisholm DJ and Storlien LH. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 1991; 40: 1397-1403.
25. [25] Surwit RS, Kuhn CM, Cochrane C, McCubbin JA and Feinglos MN. Diet-induced type II diabetes in C57BL/6J mice. Diabetes 1988; 37: 1163-1167.
26. [26] Mogensen CE, Christensen CK and Vittinghus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983; 32 Suppl 2: 64-78.
27. [27] Wang XL, Lu JM, Pan CY and Tian H. [A study comparing the prevalence of urinary albumin excretion and microalbuminuria in pre-diabetes subjects]. Zhonghua Nei Ke Za Zhi 2004; 43: 170-173.
28. [28] Viberti G and Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
29. [29] Booth AA, Khalifah RG, Todd P and Hudson BG. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J Biol Chem 1997; 272: 5430-5437.
30. [30] Miyoshi H, Taguchi T, Sugiura M, Takeuchi M, Yanagisawa K, Watanabe Y, Miwa I, Makita Z and Koike T. Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice. Horm Metab Res 2002; 34: 371-377.
31. [31] Akbas EM, Demirtas L, Ozcicek A, Timuroglu A, Bakirci EM, Hamur H, Ozcicek F and Turkmen K. Association of epicardial adipose tissue, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with diabetic nephropathy. Int J Clin Ex Med 2014; 7: 1794-1801.
32. [32] Kashihara N, Haruna Y, Kondeti VK and Kanwar YS. Oxidative stress in diabetic nephropathy. Curr Med Chem 2010; 17: 4256-4269.
33. [33] Oliveira M, Santos MA and Pacheco M. Glutathione protects heavy metal-induced inhibition of hepatic microsomal ethoxyresorufin O-deethylase activity in Dicentrarchus labrax L. Ecotoxicol Environ Saf 2004; 58: 379-385.
34. [34] Li T, Shi Y, Yin J, Qin Q, Wei S, Nie S and Liu L. The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis. Int Urol Nephrol 2015; 47: 117-30.
35. [35] Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. Am Heart J 2010; 160: 785-794, e710.
36. [36] Choudhary N and Ahlawat RS. Interleukin-6 and C-reactive protein in pathogenesis of diabetic nephropathy: new evidence linking inflammation, glycemic control, and microalbuminuria. Iran J Kidney Dis 2008; 2: 72-79.
37. [37] Branchetti E, Poggio P, Sainger R, Shang E, Grau JB, Jackson BM, Lai EK, Parmacek MS, Gorman RC, Gorman JH, Bavaria JE and Ferrari G. Oxidative stress modulates vascular smooth muscle cell phenotype via CTGF in thoracic aortic aneurysm. Cardiovasc Res 2013; 100: 316-324.
38. [38] Chen MM, Lam A, Abraham JA, Schreiner GF and Joly AH. CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 2000; 32: 1805-1819.
39. [39] Eberlein M, Heusinger-Ribeiro J and Goppelt-Struebe M. Rho-dependent inhibition of the induction of connective tissue growth factor (CTGF) by HMG CoA reductase inhibitors (statins). Br J Pharmacol 2001; 133: 1172-1180.